2

of

Sheet 2

Evaminer

PTO/SB/08B (01-08)

Approved for use through 01/31/2008, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

050992.0400.01USCP

Under the Pacework Reduction Act of 1995, no persons are required to respond to a collection of information unities 2 contains a valid OME control number.

Substitute for form 1449PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

Filing Date

May 24, 2004

First Named Inventor

Itzhak Bentwich

Art Unit

1635

Examiner Name

WOLLENBERGER, LOUIS V

Attorney Docket Number

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1		
	C11	LERAT, E. From Gene Trees to Organismal Phylogeny in Prokaryotes: The Case of the gamma-Proteobacteria. PLoS Biology 2003;1(1):101-9.	
	C12	OLSEN, LC. Human uracil-DNA glycosylase complements E.coli ung mutants. Nucleic Acids Research 1991;19(16):4473-8.	
	C13	VENKATESH. J. Importance of Uracil DNA Glycosylase in Pseudomonas aeruginosa and Mycobacterium smegmatis, G-C-rich Bacteria, in Mutation Prevention, Tolerance to Acidfiled Nitrle, and Endurance in Mouse Macrophages. The Journal of Biological Chemistry 2005; 278(27):24850-8.	
	ALI	REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.W./	

Signature	/Louis Wollenberger/	Considered	02/07/2009

Date

00/07/0000

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a chock mark here if English language Translation is attached.
This collection of information is required by 37 CFR 138. The information is required to obtain or retain a benefit by the public which is to file and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and userhingin the correlated application form to the USPTO. This will very depending upon the individual case. Any comments on the application of the control of the